(Q43824897)

English

Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group

scientific article published in November 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

based on heuristic

inferred from title

rhabdomyosarcoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Sandler E

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Lyden E

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Ruymann F

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Maurer H

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Wharam M

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Parham D

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Link M

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Crist W

8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

1 November 2001

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Pediatric Blood Cancer

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

442-448

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Biology and therapy of pediatric rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

The Intergroup Rhabdomyosarcoma Study-I. A final report

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

The Intergroup Rhabdomyosarcoma Study-II.

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy.

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma?

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Rhabdomyosarcoma of childhood.

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

The Third Intergroup Rhabdomyosarcoma Study

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Adriamycin--an antitumor antibiotic in the treatment of neoplastic diseases

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Ifosfamide--current aspects and perspectives

1 reference

https://api.crossref.org/works/10.1002%2FMPO.1227

21 January 2018

Identifiers

10.1002/MPO.1227

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43824897&oldid=2103679677"